These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

458 related items for PubMed ID: 25821144

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Cost-Effectiveness Analysis of Prophylaxis Treatment Strategies to Reduce the Incidence of Febrile Neutropenia in Patients with Early-Stage Breast Cancer or Non-Hodgkin Lymphoma.
    Fust K, Li X, Maschio M, Villa G, Parthan A, Barron R, Weinstein MC, Somers L, Hoefkens C, Lyman GH.
    Pharmacoeconomics; 2017 Apr; 35(4):425-438. PubMed ID: 27928760
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Cost-effectiveness of pegfilgrastim versus 6-day filgrastim primary prophylaxis in patients with non-Hodgkin's lymphoma receiving CHOP-21 in United States.
    Lyman G, Lalla A, Barron R, Dubois RW.
    Curr Med Res Opin; 2009 Feb; 25(2):401-11. PubMed ID: 19192985
    [Abstract] [Full Text] [Related]

  • 7. Efficacy, effectiveness and safety of long-acting granulocyte colony-stimulating factors for prophylaxis of chemotherapy-induced neutropenia in patients with cancer: a systematic review.
    Pfeil AM, Allcott K, Pettengell R, von Minckwitz G, Schwenkglenks M, Szabo Z.
    Support Care Cancer; 2015 Feb; 23(2):525-45. PubMed ID: 25284721
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Febrile neutropenia (FN) and pegfilgrastim prophylaxis in breast cancer and non-Hodgkin's lymphoma patients receiving high (> 20%) FN-risk chemotherapy: results from a prospective observational study.
    Salmon JP, Smakal M, Karanikiotis C, Wojtukiewicz MZ, Omnes Y, DeCosta L, Wetten S, O'Kelly J.
    Support Care Cancer; 2019 Apr; 27(4):1449-1457. PubMed ID: 30259136
    [Abstract] [Full Text] [Related]

  • 10. Pegfilgrastim in primary prophylaxis of febrile neutropenia following frontline bendamustine plus rituximab treatment in patients with indolent non-Hodgkin lymphoma: a single center, real-life experience.
    Cerchione C, De Renzo A, Di Perna M, Della Pepa R, Pugliese N, Catalano L, Pane F, Picardi M.
    Support Care Cancer; 2017 Mar; 25(3):839-845. PubMed ID: 27812763
    [Abstract] [Full Text] [Related]

  • 11. Routine Primary Prophylaxis for Febrile Neutropenia with Biosimilar Granulocyte Colony-Stimulating Factor (Nivestim) or Pegfilgrastim Is Cost Effective in Non-Hodgkin Lymphoma Patients undergoing Curative-Intent R-CHOP Chemotherapy.
    Wang XJ, Tang T, Farid M, Quek R, Tao M, Lim ST, Wee HL, Chan A.
    PLoS One; 2016 Mar; 11(2):e0148901. PubMed ID: 26871584
    [Abstract] [Full Text] [Related]

  • 12. Cost-effectiveness of granulocyte colony-stimulating factors (G-CSFs) for the prevention of febrile neutropenia (FN) in patients with cancer.
    Aapro MS, Chaplin S, Cornes P, Howe S, Link H, Koptelova N, Mehl A, Di Palma M, Schroader BK, Terkola R.
    Support Care Cancer; 2023 Sep 20; 31(10):581. PubMed ID: 37728795
    [Abstract] [Full Text] [Related]

  • 13. Efficacy and safety of lipegfilgrastim versus pegfilgrastim in elderly patients with aggressive B cell non-Hodgkin lymphoma (B-NHL): results of the randomized, open-label, non-inferiority AVOID neutropenia study.
    Link H, Illerhaus G, Martens UM, Salar A, Depenbusch R, Köhler A, Engelhardt M, Mahlmann S, Zaiss M, Lammerich A, Bias P, Buchner A.
    Support Care Cancer; 2021 May 20; 29(5):2519-2527. PubMed ID: 32944800
    [Abstract] [Full Text] [Related]

  • 14. Observational study of the prevalence of febrile neutropenia in patients who received filgrastim or pegfilgrastim associated with 3-4 week chemotherapy regimens in community oncology practices.
    Morrison VA, Wong M, Hershman D, Campos LT, Ding B, Malin J.
    J Manag Care Pharm; 2007 May 20; 13(4):337-48. PubMed ID: 17506600
    [Abstract] [Full Text] [Related]

  • 15. Trends in the use of primary prophylactic colony-stimulating factors and neutropenia-related hospitalization in elderly cancer patients receiving myelosuppressive chemotherapy in the USA: 1995-2015.
    Li S, Liu J, Guo H, Gawade PL, Kim C, Bensink ME, Chandler D.
    Support Care Cancer; 2020 Jun 20; 28(6):2637-2649. PubMed ID: 31624920
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Cost-effectiveness of pegfilgrastim versus filgrastim for prevention of chemotherapy-induced febrile neutropenia in patients with lymphoma: a systematic review.
    Gebremariam GT, Fentie AM, Beyene K, Sander B, Gebretekle GB.
    BMC Health Serv Res; 2022 Dec 30; 22(1):1600. PubMed ID: 36585648
    [Abstract] [Full Text] [Related]

  • 18. Chemotherapy-associated treatment burden in breast cancer patients receiving lipegfilgrastim or pegfilgrastim: secondary efficacy data from a phase III study.
    Gladkov OA, Buchner A, Bias P, Müller U, Elsässer R.
    Support Care Cancer; 2016 Jan 30; 24(1):395-400. PubMed ID: 26092233
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.